These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28061552)

  • 41. Development of a dinutuximab delivery system using silk foams for GD2 targeted neuroblastoma cell death.
    Ornell KJ; Chiu B; Coburn JM
    J Biomed Mater Res A; 2021 Aug; 109(8):1393-1405. PubMed ID: 33252182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
    Pennington B; Ren S; Barton S; Bacelar M; Edwards SJ
    Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Case of Anti-NMDA Receptor Encephalitis During Dinutuximab Therapy for Neuroblastoma.
    Lowas SR; Lettieri CK
    J Pediatr Hematol Oncol; 2021 Jan; 43(1):e127-e129. PubMed ID: 31651725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.
    Lode HN; Ladenstein R; Troschke-Meurer S; Struppe L; Siebert N; Zumpe M; Ehlert K; Huber S; Glogova E; Hundsdoerfer P; Eggert A; Zaniewska-Tekieli A; Balwierz W; Wieczorek A
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444475
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dinutuximab approved for high-risk neuroblastoma.
    Cancer Discov; 2015 Jun; 5(6):OF5. PubMed ID: 25851859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis.
    Emberesh M; Rubinstein JD; Young J; Benoit SW; Dandoy CE; Weiss BD
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28852. PubMed ID: 33381917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
    Voeller J; Sondel PM
    J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
    Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
    JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Yoga as a non-pharmacologic therapy to reduce dinutuximab-induced pain in patients with neuroblastoma.
    Parisio KN; Kulp T; Heil M; Li Y; Dalton K; McGrath M; Carlowicz C; Donnelly M; Bagatell R; Jubelirer T
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30845. PubMed ID: 38192171
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma.
    Spasov N; Spasova M
    Case Rep Pediatr; 2021; 2021():6610955. PubMed ID: 34239748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
    Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
    J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.
    Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Niethammer D; Berthold F
    J Clin Oncol; 2004 Sep; 22(17):3549-57. PubMed ID: 15337804
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
    Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
    MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Restricting Access to Hope: A Parent's Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab.
    Bernstein J
    Pediatr Blood Cancer; 2016 Jun; 63(6):964-5. PubMed ID: 26918436
    [No Abstract]   [Full Text] [Related]  

  • 56. Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus.
    Nysom K; Morad AG; Rafael MS; Zier J; Marachelian A; Watt T; Morgenstern DA
    Pediatr Blood Cancer; 2023 May; 70(5):e30217. PubMed ID: 36772891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients.
    Blom T; Lurvink R; Aleven L; Mensink M; Wolfs T; Dierselhuis M; van Eijkelenburg N; Kraal K; van Noesel M; van Grotel M; Tytgat G
    Front Oncol; 2020; 10():601076. PubMed ID: 33680926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.
    Troschke-Meurer S; Zumpe M; Meißner L; Siebert N; Grabarczyk P; Forkel H; Maletzki C; Bekeschus S; Lode HN
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765861
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
    Görges M; West N; Deyell R; Winton P; Cheung W; Lauder G
    Pediatr Blood Cancer; 2015 Jan; 62(1):29-34. PubMed ID: 25263424
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia.
    Giljević JS; Rajačić N; Mikulić D; Batoš AT
    Children (Basel); 2022 Jun; 9(7):. PubMed ID: 35883927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.